Research is underway on a new no-needle vaccine that scientists believe has the potential to be better than injected vaccines.Cincinnati Children’s Hospital is enrolling in the trial.“This is a trial of an experimental COVID vaccine by administration in the nose,” said Children’s Hospital Dr. Paul Spearman.For many, the lack of needles is enough to give it an advantage over all other COVID-19 vaccines, but researchers say there are other reasons.“It has the potential advantage of mucosal immunity, meaning right at the site where the virus might attack. That could prevent the initial infection. That could also prevent the spread of the virus,” Spearman said.Children’s is one of three sites around the country studying the nasal COVID-19 vaccine.The trial is seeking a specific type of participant. The study will look at adults who have not had COVID-19 and have not had the vaccine for it.“It’s a challenge,” Spearman said. “It’s a special group of people we’re really looking for.”Researchers just opened enrollment. So far, they have 11 adults signed up, but they’re hoping to get about 80.The new vaccine uses a live virus like other nasal vaccines for influenza. This one has a vector not used in humans before, but scientists believe it is safe because people have had contact with it through their pets.“The Pi5 virus itself, parainfluenza virus type 5, is part of the kennel cough vaccine that’s given to dogs, and people get exposed to that. We know they do because that’s been evaluated and as far as we know, they’ve never had symptoms,” Spearman said.Participants get a $975.00 incentive, but even though it’s a no-needle vaccine, those who take part in the study will have to have blood drawn with a needle.To enroll, click here redcap.link/COVID-19Vaccine
CINCINNATI —
Research is underway on a new no-needle vaccine that scientists believe has the potential to be better than injected vaccines.
Cincinnati Children’s Hospital is enrolling in the trial.
“This is a trial of an experimental COVID vaccine by administration in the nose,” said Children’s Hospital Dr. Paul Spearman.
For many, the lack of needles is enough to give it an advantage over all other COVID-19 vaccines, but researchers say there are other reasons.
“It has the potential advantage of mucosal immunity, meaning right at the site where the virus might attack. That could prevent the initial infection. That could also prevent the spread of the virus,” Spearman said.
Children’s is one of three sites around the country studying the nasal COVID-19 vaccine.
The trial is seeking a specific type of participant. The study will look at adults who have not had COVID-19 and have not had the vaccine for it.
“It’s a challenge,” Spearman said. “It’s a special group of people we’re really looking for.”
Researchers just opened enrollment. So far, they have 11 adults signed up, but they’re hoping to get about 80.
The new vaccine uses a live virus like other nasal vaccines for influenza.
This one has a vector not used in humans before, but scientists believe it is safe because people have had contact with it through their pets.
“The Pi5 virus itself, parainfluenza virus type 5, is part of the kennel cough vaccine that’s given to dogs, and people get exposed to that. We know they do because that’s been evaluated and as far as we know, they’ve never had symptoms,” Spearman said.
Participants get a $975.00 incentive, but even though it’s a no-needle vaccine, those who take part in the study will have to have blood drawn with a needle.
To enroll, click here redcap.link/COVID-19Vaccine